Carna Biosciences, Inc.
4572.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.06B
Close$
Share Statistics
| Market cap | $7.06 Billion |
|---|---|
| Enterprise Value | $7.95 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-113.62 |
| Beta | 0.28 |
| Outstanding Shares | 19,988,772 |
Return
| Return on Equity | 528.44% |
|---|---|
| Return on Assets | -122.07% |
| Return on Invested Capital | -122.28% |
Valuation & Multiples
| P/E Ratio | -3.3 |
|---|---|
| PEG | 60.4 |
| Price to Sales | 10.22 |
| Price to Book Ratio | -17.52 |
| Enterprise Value to Revenue | 10.9 |
| Enterprise Value to EBIT | -4 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | -4.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Carna Biosciences, Inc.
61 employees
CEO: Kohichiro Yoshino Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly ...